Incyte Announces Departure of Chief Financial Officer Christiana Stamoulis
– Company initiates search for successor and reaffirms full year financial guidance
WILMINGTON, Del.–(BUSINESS WIRE)–
Incyte (Nasdaq:INCY) today announced that Christiana Stamoulis will step down from her role as Executive Vice President and Chief Financial Officer (CFO) to pursue another opportunity, effective September 16, 2025. Ms. Stamoulis will remain with the Company until then to support a smooth transition. The Company has initiated the process of appointing a successor.
“Since joining Incyte in 2019, Christiana has been an invaluable part of the leadership team. I would like to take this opportunity to thank Christiana for her many contributions, and wish her well in her future endeavors,” said Bill Meury, President and Chief Executive Officer of Incyte. “As we search for our next CFO, our focus is on finding a strategic leader to execute our long-term growth plan.”
The Company reaffirms its previously issued financial guidance for 2025, as disclosed during its second-quarter earnings announcement on July 29, 2025. The Company’s financial position and strategic direction remain unchanged.
About Incyte
A global biopharmaceutical company on a mission to Solve On., Incyte follows the science to find solutions for patients with unmet medical needs. Through the discovery, development and commercialization of proprietary therapeutics, Incyte has established a portfolio of first-in-class medicines for patients and a strong pipeline of products in Oncology and Inflammation & Autoimmunity. Headquartered in Wilmington, Delaware, Incyte has operations in North America, Europe and Asia.
For additional information on Incyte, please visit Incyte.com or follow us on social media: LinkedIn, X, Instagram, Facebook, YouTube.
Forward-Looking Statements
Except for the historical information set forth herein, the matters set forth in this release contain predictions, estimates and other forward-looking statements, including any discussion of Incyte’s financial guidance for 2025, its strategic direction and plan for long-term growth.
These forward-looking statements are based on Incyte’s current expectations and subject to risks and uncertainties that may cause actual results to differ materially, including unanticipated developments in and risks related to: further research and development and the results of clinical trials possibly being unsuccessful or insufficient to meet applicable regulatory standards or warrant continued development; the ability to enroll sufficient numbers of subjects in clinical trials and the ability to enroll subjects in accordance with planned schedules; determinations made by the FDA, EMA and other regulatory agencies; Incyte’s dependence on its relationships with and changes in the plans of its collaboration partners; the efficacy or safety of Incyte’s products and the products of Incyte’s collaboration partners; the acceptance of Incyte’s products and the products of Incyte’s collaboration partners in the marketplace; market competition; unexpected variations in the demand for Incyte’s products and the products of Incyte’s collaboration partners; the effects of announced or unexpected price regulation or limitations on reimbursement or coverage for Incyte’s products and the products of Incyte’s collaboration partners; sales, marketing, manufacturing and distribution requirements, including Incyte’s and its collaboration partners’ ability to successfully commercialize and build commercial infrastructure for newly approved products and any additional products that become approved; greater than expected expenses, including expenses relating to litigation or strategic activities; variations in foreign currency exchange rates; and other risks detailed in Incyte’s reports filed with the Securities and Exchange Commission, including its annual report on form 10-K and its report on form 10-Q for the quarter ended June 30, 2025. Incyte disclaims any intent or obligation to update these forward-looking statements.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250805985070/en/
Media
[email protected]
Investors
[email protected]
KEYWORDS: United States North America Delaware
INDUSTRY KEYWORDS: Biotechnology Pharmaceutical Health
MEDIA:
| Logo |
 |